Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Bone. 2020 Jun 23;138:115492. doi: 10.1016/j.bone.2020.115492

Figure 6. Bone-targeted UR70 reduces tumor burden in mice bearing Btz-resistant myeloma cells.

Figure 6.

(A) Treatment protocol for 7-wk-old male NSG mice given injections of 0.5 × 106 Btz-resistant 5TGM1-GFP mouse myeloma cells into each tibia. 3 days after tumor cell inoculation, mice were given retro-orbital intravenous injections of equimolar concentrations of the BP (0.699mg/kg), Btz (0.6mg/kg) or UR70 (1.722mg/kg) every 3 days for 8 cycles. (B) Representative images of legs from mice from each group 3 days after the last injection, visualized with an IVIS Spectrum in vivo imaging system and showing GFP-positive tumor in the injected tibiae. (C) Tumor burden assessed by GFP intensity. Unit: Average Radiant Efficiency [p/s/cm2/sr] / [μW/cm2]. Data are mean ± SD. One-way ANOVA with Turkey’s test. *: p<0.05 vs vehicle.